LXRX Financial Facts
Collaborative research: 27.69MTotal revenues: 27.72M
See Full Income Statement
Accounts receivable, net of allowances of $35: 738K
Current portion of deferred revenue: 78.87M
See Full Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings
|
Expand Research on LXRX
| Next EPS Date | 5/2/24 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -6.9% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -8.0% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/7/15  |
 |
Q215 | -$0.27 | -$0.32 | +$0.05 | $376M | $360K | N/A |  | | Details |
| 11/7/19 | |
Q319 | $1.95 | $0.73 | +$1.22 | $294.45M | $64.25M | N/A | | | Details |
| 5/8/14 |
|
Q114 | -$0.06 | -$0.05 | -$0.01 | $277M | $120K | N/A | | | Details |
| 7/30/13 | Q113 | -$0.06 | -$0.05 | -$0.01 | $214M | $280K | N/A | | | Details | |
| 3/1/16 |
|
Q415 | $0.76 | N/A | N/A | $127.3M | $21.5M | N/A | | | Details |
| 2/22/18 | |
Q417 | -$0.27 | -$0.41 | +$0.14 | $33M | $29.98M | = | | | Details |
| 11/1/16 |
|
Q316 | -$0.35 | -$0.49 | +$0.14 | $27.7M | $9.68M | N/A | | | Details |
| 11/8/17 | |
Q317 | -$0.29 | -$0.36 | +$0.07 | $26.94M | $27.96M | = | | | Details |
